Achilles Therapeutics

64 articles about Achilles Therapeutics

• Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors

  5/4/2022

  Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of Bernhard Ehmer, MD, to the Board as a Non-Executive Director.

• Achilles Therapeutics to Present at Upcoming Conferences

  5/3/2022

  Achilles Therapeutics plc today announced that the Company will be taking part in the following conferences in May.

• 

  Global Roundup: A CAR-T Partnership and CDR-Life Nabs $76M to Engage Solid Tumors

  4/14/2022

  Australia’s Chimeric Therapeutics has partnered with WuXi ATU on two autologous CAR T-cell therapies for solid tumors. Switzerland-based CDR-Life closed a $76 million Series A.

• Achilles Therapeutics Announces Manufacturing Expansion in the UK and Partnership for Manufacturing in the US

  4/12/2022

  Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, announced clinical manufacturing expansion in the United Kingdom and the United States.

• Achilles Therapeutics to Present at Upcoming Conferences - Apr 05, 2022

  4/5/2022

  Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, announced that management will be taking part in the following conferences in April.

• Achilles Therapeutics to Host KOL Webcast to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting

  4/4/2022

  Achilles Therapeutics plc announced that the Company will host a key opinion leader webcast to discuss the importance and unique utility of the TRACERx study in validating the identification of clonal neoantigens as targets for personalized T cell therapies and to highlight selections from the 31 posters and presentations on the TRACERx study presented at the 2022 American Association for Cancer Research Annual Meeting.

• Achilles Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference

  3/8/2022

  Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, announced its participation in the 32nd Annual Oppenheimer Healthcare Conference taking place virtually March 15 - 17, 2022.

• Achilles Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Business Highlights

  3/1/2022

  Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its financial results for the fourth quarter and year-ended December 31, 2021, and recent business highlights.

• 

  BioSpace Movers & Shakers, Feb. 11

  2/11/2022

  Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.

• Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D.

  2/7/2022

  Achilles Therapeutics plc today announced the appointment of Alena Gros, Ph.D. and Ben Creelan, M.D. to its Scientific Advisory Board (SAB).

• 

  JPM Day 3: AbbVie Sees Bright Future Ahead, vTv, Gritstone and Achilles

  1/13/2022

  Looking at long-term growth, Michael said that will be driven by numerous differentiated assets across each of Abbvie’s core areas.

• Achilles Therapeutics Provides Business Update and Outlook for 2022

  1/13/2022

  Achilles Therapeutics plc today announces a business update and reflects on recent progress with its pioneering, personalized T cell therapy programs targeting clonal neoantigens known as cNeT.

• Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference

  12/21/2021

  Achilles Therapeutics plc announced that Iraj Ali, Chief Executive Officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022, at 8:15 a.m. ET.

• Achilles Therapeutics Added to the NASDAQ Biotechnology Index

  12/20/2021

  Achilles Therapeutics plc announced that the Company has been added to the NASDAQ Biotech Index, effective prior to market open, Monday, December 20, 2021.

• Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens

  12/9/2021

  Achilles Therapeutics plc today presented positive data at the ESMO Immuno-Oncology Congress 2021.

• Achilles Therapeutics Presents Data at the Society for Immunotherapy of Cancer Annual Meeting Demonstrating the Ability to Detect, Quantify and Track Patient-specific cNeT & Significant Increase in cNeT Dose from VELOS™ Process 2 Manufacturing

  11/12/2021

  Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, presented two posters at the Society for Immunotherapy of Cancer Annual Meeting demonstrating the ability to detect, quantify, and track patient-specific clonal neoantigen-reactive T cells and generate increased cNeT doses from VELOS™ Process 2 manufacturing.

• Secarna Pharmaceuticals and Achilles Therapeutics Sign Research, Option and License Agreement to Develop Optimized T Cell Therapies

  11/10/2021

  Secarna Pharmaceuticals GmbH & Co. KG today announced that the Company has entered into a research, option and license agreement with Achilles Therapeutics UK Limited ("Achilles"), a member of the Achilles Therapeutics plc (NASDAQ:ACHL) group of companies, in the field of immune oncology.

• Achilles Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights

  11/9/2021

  Achilles Therapeutics plc today announced its financial results for the third quarter ended September 30, 2021, and recent business highlights.

• Achilles Therapeutics Presents Data at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress

  10/22/2021

  Achilles Therapeutics plc today delivered an oral presentation (OR54) at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress.

• Achilles Therapeutics to Present at Upcoming Scientific Congresses

  10/1/2021

  Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, will present an oral presentation at the 2021 European Society for Gene and Cell Therapy (ESGCT) Congress being held in a virtual format from October 19-22, 2021, and two posters at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting.